Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Oncotarget

Volumn 8, Issue 2, 2017, Pages 3581-3590

  Fendler, Wolfgang P ^a,b   Reinhardt, Svenja ^a   Ilhan, Harun ^a   Delker, Andreas ^a   Böning, Guido ^a   Gildehaus, Franz J ^a   Stief, Christian ^a,c   Bartenstein, Peter ^a   Gratzke, Christian ^a,c   Lehner, Sebastian ^a   Rominger, Axel ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Lutetium; mCRPC; PET; Prostate cancer; PSMA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DIAGNOSTIC AGENT; GALLIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; LUTETIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 177LU-PSMA-617; ANTINEOPLASTIC AGENT; DIPEPTIDE; LUTETIUM; SINGLE HETEROCYCLIC RINGS;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BONE PAIN; BRIEF PAIN INVENTORY; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; LEUKOCYTE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PAIN INTENSITY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RADIATION DOSE; RENAL SYSTEM PARAMETERS; SALIVARY GLAND FUNCTION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; THROMBOCYTOPENIA; TUBULAR EXTRACTION RATE; XEROSTOMIA; CANCER GRADING; CANCER STAGING; DIAGNOSTIC IMAGING; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT-REPORTED OUTCOME; RADIOMETRY; RETREATMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMBINED MODALITY THERAPY; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LUTETIUM; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT REPORTED OUTCOME MEASURES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOMETRY; RETREATMENT;

EID: 85009751119     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12240     Document Type: Article

References (33)

1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2163-2196
2. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369:213-223
3. Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF and Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014; 65:3-6
4. Ghosh A and Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004; 91:528-539
5. Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K and Eder M. Preclinical Evaluation of a Tailor-Made DOTAConjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015; 56:914-920
6. Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P and Boning G. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016; 43:42-51
7. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ and Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21:109-122
8. Gensheimer MF, Liao JJ, Garden AS, Laramore GE and Parvathaneni U. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. Radiat Oncol. 2014; 9:255
9. Hey J, Setz J, Gerlach R, Janich M, Hildebrandt G, Vordermark D, Gernhardt CR and Kuhnt T. Parotid glandrecovery after radiotherapy in the head and neck region-36 months follow-up of a prospective clinical study. Radiat Oncol. 2011; 6:125
10. FROM ECC 2015-neuroendocrine cancer: SSA therapies-(177)Lu-DOTATATE is a better one in NETTER-1. Nat Rev Clin Oncol. 2015; 12:684
11. Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, Haberkorn U and Eisenhut M. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23:688-697
12. Gupta SK, Singla S, Thakral P and Bal CS. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE. Clin Nucl Med. 2013; 38:188-194
13. Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E and Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostatespecific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42:1976-1983
14. Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K and Haberkorn U. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016; 57:1170-6
15. Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gartner F, Rogenhofer S and Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016; 7:12477-88. doi: 10.18632/oncotarget.7245
16. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M and Ahmadzadehfar H. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016
17. Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A and Bal C. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2016
18. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, Gartner F, Rogenhofer S, Schafers M and Essler M. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015; 5:114
19. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, Kopka K and Haberkorn U. [(177) Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42:987-988
20. Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L and Bogemann M. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. Clin Nucl Med. 2016; 41:522-528
21. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I and Wester HJ. Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016; 57:1006-13
22. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW and Haberkorn U. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014; 41:1280-1292
23. Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R et al. Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J Urol. 2016; 196:382-91
24. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371:1028-1038
25. Morris MJ, Autio KA, Basch EM, Danila DC, Larson S and Scher HI. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol. 2013; 40:375-392
26. Verbel DA, Heller G, Kelly WK and Scher HI. Quantifying the amount of variation in survival explained by prostatespecific antigen. Clin Cancer Res. 2002; 8:2576-2579
27. Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, Drzezga A and Wild M. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016; 18:437-445
28. Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lutzen U, Prasad V, Heinzel A, Heuschkel M, Ruf J, Bartenstein P, et al. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016; 55:123-128
29. Institute NC. (2006). Common Terminology Criteria for Adverse Events v3.0.: NCI, NIH, DHHS)
30. Institute NC. (2009). Common Terminology Criteria for Adverse Events v4.0.: NCI, NIH, DHHS)
31. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C and Fendler WP. Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol. 2016
32. Daut RL, Cleeland CS and Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983; 17:197-210
33. Esper P, Mo F, Chodak G, Sinner M, Cella D and Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997; 50:920-928